1
|
Gether L, Storgaard H, Kezic S, Jakasa I, Hartmann B, Skov-Jeppesen K, Holst JJ, Pedersen AJ, Forman J, van Hall G, Sørensen OE, Skov L, Røpke MA, Knop FK, Thyssen JP. Effects of topical corticosteroid versus tacrolimus on insulin sensitivity and bone homeostasis in adults with atopic dermatitis-A randomized controlled study. Allergy 2023. [PMID: 36824052 DOI: 10.1111/all.15690] [Citation(s) in RCA: 2] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/12/2022] [Revised: 01/06/2023] [Accepted: 01/24/2023] [Indexed: 02/25/2023]
Abstract
INTRODUCTION Topical corticosteroids (TCS), used to treat atopic dermatitis (AD), have been associated with type 2 diabetes and osteoporosis in epidemiological studies, possibly explained by systemic absorption. OBJECTIVES We examined whether intensive daily whole-body TCS treatment over 2 weeks followed by twice weekly application for 4 weeks could elicit insulin resistance and increase bone resorption in adults with AD. METHODS A randomized parallel-group double-blind double-dummy non-corticosteroid-based active comparator study design was completed in Copenhagen, Denmark. Thirty-six non-obese, non-diabetic adults with moderate-to-severe AD were randomized to whole-body treatment with betamethasone 17-valerate 0.1% plus a vehicle once daily or tacrolimus 0.1% twice daily after washout. Insulin sensitivity assessed by the hyperinsulinemic-euglycemic clamp combined with tracer infusions and biomarkers of bone formation (P1NP) and resorption (CTX) were evaluated at baseline, after 2 weeks of daily treatment and after further 4 weeks of twice-weekly maintenance treatment. RESULTS AD severity improved with both treatments and systemic inflammation was reduced. After 2 weeks, we observed similar increase in peripheral insulin sensitivity with use of betamethasone (n = 18) and tacrolimus (n = 18). Bone resorption biomarker, CTX, was unchanged, while bone formation marker, P1NP, decreased after betamethasone treatment after both 2 and 6 weeks but remained unchanged in the tacrolimus arm. CONCLUSIONS Whole-body treatment with TCS leads to systemic exposure but appears not to compromise glucose metabolism during short-term use, which may be a result of reduced systemic inflammatory activity. The negative impact on bone formation could be regarded an adverse effect of TCS.
Collapse
Affiliation(s)
- Lise Gether
- Center for Clinical Metabolic Research, Herlev-Gentofte Hospital, University of Copenhagen, Hellerup, Denmark
- Department of Dermatology and Allergy, Copenhagen Research Group for Inflammatory Skin (CORGIS), Herlev-Gentofte Hospital, University of Copenhagen, Hellerup, Denmark
- LEO Pharma A/S, Ballerup, Denmark
| | - Heidi Storgaard
- Center for Clinical Metabolic Research, Herlev-Gentofte Hospital, University of Copenhagen, Hellerup, Denmark
- Steno Diabetes Center Copenhagen, Copenhagen, Denmark
| | - Sanja Kezic
- Department of Public and Occupational Health, Amsterdam UMC, University of Amsterdam, Amsterdam, Netherlands
| | - Ivone Jakasa
- Department of Chemistry and Biochemistry, Laboratory for Analytical Chemistry, Faculty of Food Technology and Biotechnology, University of Zagreb, Zagreb, Croatia
| | - Bolette Hartmann
- Department of Biomedical Sciences, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark
- Novo Nordisk Foundation Center for Basic Metabolic Research, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark
| | - Kirsa Skov-Jeppesen
- Department of Biomedical Sciences, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark
- Novo Nordisk Foundation Center for Basic Metabolic Research, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark
| | - Jens J Holst
- Department of Biomedical Sciences, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark
- Novo Nordisk Foundation Center for Basic Metabolic Research, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark
| | | | - Julie Forman
- Section of Biostatistics, Department of Public Health, University of Copenhagen, Copenhagen, Denmark
| | - Gerrit van Hall
- Department of Biomedical Sciences, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark
- Clinical Metabolomics Core Facility, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark
| | | | - Lone Skov
- Department of Dermatology and Allergy, Copenhagen Research Group for Inflammatory Skin (CORGIS), Herlev-Gentofte Hospital, University of Copenhagen, Hellerup, Denmark
- Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark
| | - Mads A Røpke
- LEO Pharma A/S, Ballerup, Denmark
- Department of Immunology and Microbiology, University of Copenhagen, Copenhagen, Denmark
| | - Filip K Knop
- Center for Clinical Metabolic Research, Herlev-Gentofte Hospital, University of Copenhagen, Hellerup, Denmark
- Novo Nordisk Foundation Center for Basic Metabolic Research, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark
- Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark
| | - Jacob Pontoppidan Thyssen
- Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark
- Department of Dermatology and Venereology, Bispebjerg-Frederiksberg Hospital, University of Copenhagen, Copenhagen, Denmark
| |
Collapse
|
2
|
Kogame T, Yonekura S, Lovato P, Hirata M, Takimoto-Ito R, Takegami T, Komatsu-Fujii T, Kambe N, Nomura T, Røpke MA, Kabashima K. Interleukin-13 inhibition by tralokinumab reduces inducible T-cell costimulator-positive innate lymphoid cells in skin lesions of atopic dermatitis. Br J Dermatol 2023; 188:146-148. [PMID: 36689531 DOI: 10.1093/bjd/ljac008] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/18/2022] [Revised: 09/02/2022] [Accepted: 09/24/2022] [Indexed: 01/22/2023]
Abstract
Despite the low frequency of skin ILCs and the limited number of samples analyzed in this study, our data indicate that ICOS+ ILCs express IL-13Rα1 and that the density of ICOS+ ILCs decreased four weeks after initiation of treatment with tralokinumab.
Collapse
Affiliation(s)
- Toshiaki Kogame
- Department of Dermatology, Kyoto University Graduate School of Medicine, Kyoto, Japan
| | - Satoru Yonekura
- Department of Dermatology, Kyoto University Graduate School of Medicine, Kyoto, Japan
| | | | - Masahiro Hirata
- Department of Diagnostic Pathology, Kyoto University Hospital, Kyoto, Japan
| | - Riko Takimoto-Ito
- Department of Dermatology, Kyoto University Graduate School of Medicine, Kyoto, Japan
| | - Tomoya Takegami
- Department of Dermatology, Kyoto University Graduate School of Medicine, Kyoto, Japan
| | | | - Naotomo Kambe
- Department of Dermatology, Kyoto University Graduate School of Medicine, Kyoto, Japan
| | - Takashi Nomura
- Department of Dermatology, Kyoto University Graduate School of Medicine, Kyoto, Japan
| | | | - Kenji Kabashima
- Department of Dermatology, Kyoto University Graduate School of Medicine, Kyoto, Japan
| |
Collapse
|
3
|
Olydam JI, de Wijs LEM, Dik WA, Røpke MA, Da Rosa JC, Hijnen DJ. EASI p-EASI: Predicting Disease Severity in Patients with Atopic Dermatitis Treated with Tralokinumab. J Invest Dermatol 2022; 142:3335-3337.e1. [PMID: 35843313 DOI: 10.1016/j.jid.2022.06.008] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/11/2022] [Revised: 06/07/2022] [Accepted: 06/10/2022] [Indexed: 01/05/2023]
Affiliation(s)
- Jill I Olydam
- Department of Dermatology, Erasmus University Medical Center, Rotterdam, The Netherlands
| | - Linde E M de Wijs
- Department of Dermatology, Erasmus University Medical Center, Rotterdam, The Netherlands
| | - Willem A Dik
- Laboratory Medical Immunology, Department of Immunology, Erasmus MC, University Medical Center, Rotterdam, The Netherlands
| | - Mads A Røpke
- Department of Clinical Pharmacology, LEO Pharma A/S, Ballerup, Denmark
| | - Joel Correa Da Rosa
- Department of Biostatistics, The Rockefeller University Hospital, The Rockefeller University, New York, New York, USA
| | - Dirk Jan Hijnen
- Department of Dermatology, Erasmus University Medical Center, Rotterdam, The Netherlands.
| |
Collapse
|
4
|
Merola JF, Bagel J, Almgren P, Røpke MA, Lophaven KW, Vest NS, Grewal P. Tralokinumab does not impact vaccine-induced immune responses: Results from a 30-week, randomized, placebo-controlled trial in adults with moderate-to-severe atopic dermatitis. J Am Acad Dermatol 2021; 85:71-78. [PMID: 33744356 DOI: 10.1016/j.jaad.2021.03.032] [Citation(s) in RCA: 22] [Impact Index Per Article: 7.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/11/2020] [Revised: 02/23/2021] [Accepted: 03/07/2021] [Indexed: 12/18/2022]
Abstract
BACKGROUND Atopic dermatitis (AD) is a chronic inflammatory skin disease. Interleukin (IL) 13 is a type 2 cytokine that is key to the inflammation underlying AD. Tralokinumab is a first-in-class, fully human, monoclonal antibody that specifically binds with high affinity to IL-13, neutralizing it in AD. Immunomodulatory treatments may impair vaccine-induced immune responses. OBJECTIVE Assess the immune responses to standard vaccines in adults with moderate-to-severe AD who are undergoing treatment with tralokinumab. METHODS ECZema TRAlokinumab Trial No. 5 (ECZTRA 5; NCT03562377) was a phase 2, double-blind, randomized, placebo-controlled trial taking place over 30 weeks. Eligible adults were randomized 1:1, with 107 patients receiving tralokinumab 300 mg and 108 patients receiving a placebo every 2 weeks for 16 weeks. All patients received Tdap (tetanus/diphtheria/pertussis) and meningococcal vaccines at week 12. The primary end points were positive antitetanus and antimeningococcal responses between weeks 12 and 16 (noninferiority margin, -25%; responder, >3-fold increase in IgG). RESULTS The noninferiority of tralokinumab versus placebo for immune response to Tdap (91.9% vs 96.1%) and meningococcal (86.0% vs 84.2%) vaccines was demonstrated at week 16. During treatment, the rates of adverse events were lower for tralokinumab than for the placebo, with most events being mild or moderate. LIMITATIONS Responses to other vaccines (including influenza) were not examined. CONCLUSIONS Treatment with tralokinumab 300 mg every 2 weeks did not affect immune responses to Tdap and meningococcal vaccines. Treatment was well tolerated when administered concomitantly with the vaccines and demonstrated a safety profile comparable to phase 3 trials.
Collapse
Affiliation(s)
- Joseph F Merola
- Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts.
| | - Jerry Bagel
- Eczema Treatment Center of New Jersey, East Windsor, New Jersey
| | | | | | | | | | - Parbeer Grewal
- Division of Dermatology, University of Alberta, Edmonton, Canada
| |
Collapse
|
5
|
Hald M, Thyssen JP, Zachariae C, Røpke MA, Carstensen JM, Schultz N, Johansen JD. Multispectral imaging of hand eczema. Contact Dermatitis 2019; 81:438-445. [PMID: 31389010 DOI: 10.1111/cod.13377] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/13/2019] [Revised: 08/02/2019] [Accepted: 08/05/2019] [Indexed: 11/30/2022]
Abstract
BACKGROUND Hand eczema is a disease with large variation in clinical presentation and severity. Scoring systems for quantitative severity assessment exist. However, they are observer-dependent. An objective quantitative tool for scoring of hand eczema would improve categorization of hand eczema. OBJECTIVE To investigate the usefulness of multispectral imaging in assessing severity of hand eczema with respect to extent and the different morphological features. METHODS Patients with hand eczema (n = 60) and healthy controls (n = 28) were included. The severity of hand eczema was assessed by a dermatologist using the Hand Eczema Severity Index (HECSI) and a global assessment (Physician Global Assessment [PGA]). Multispectral imaging of the hand was performed on all patients and controls using the VideometerLab Instrument. RESULTS Areas of the morphological elements identified by multispectral imaging were statistically significantly correlated with the PGA scores. Analyzed by Cohen's kappa, a moderate agreement between imaging-based severity assessment and PGA was found. The imaging-based severity assessment was also correlated with HECSI (Spearman rho 0.683, P < .001). Still, the imaging-based algorithm was not capable of differentiating hand eczema patients from controls. CONCLUSIONS Multispectral imaging allows quantitative measurements of different skin parameters to be performed. In its present form, multispectral imaging cannot replace the clinical assessment of a dermatologist. However, after refinement, this or similar technologies could prove useful.
Collapse
Affiliation(s)
- Marianne Hald
- Department of Dermatology and Allergy, Herlev-Gentofte Hospital, University of Copenhagen, Hellerup, Denmark
| | - Jacob P Thyssen
- Department of Dermatology and Allergy, Herlev-Gentofte Hospital, University of Copenhagen, Hellerup, Denmark
| | - Claus Zachariae
- Department of Dermatology and Allergy, Herlev-Gentofte Hospital, University of Copenhagen, Hellerup, Denmark
| | - Mads A Røpke
- Department of Clinical Pharmacology, LEO Pharma A/S, Ballerup, Denmark
| | | | | | - Jeanne D Johansen
- National Allergy Research Centre, Department of Dermatology and Allergy, Herlev-Gentofte Hospital, University of Copenhagen, Hellerup, Denmark
| |
Collapse
|
6
|
Mose KF, Andersen F, Røpke MA, Skov L, Friedmann PS, Andersen KE. Anti-inflammatory potency testing of topical corticosteroids and calcineurin inhibitors in human volunteers sensitized to diphenylcyclopropenone. Br J Clin Pharmacol 2018; 84:1719-1728. [PMID: 29607554 PMCID: PMC6046503 DOI: 10.1111/bcp.13596] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/25/2017] [Revised: 03/13/2018] [Accepted: 03/17/2018] [Indexed: 12/01/2022] Open
Abstract
AIMS To quantify the anti-inflammatory potency of topical corticosteroids and topical calcineurin inhibitors by measuring the contact allergic response to a diphenylcyclopropenone (DPCP) challenge in de novo sensitized human volunteers. METHODS Two randomized, double-blind, vehicle-controlled studies were performed encompassing 76 volunteers: 29 in the first and 47 in the second study. Topical drugs were applied pre- and/or post-treatment in block designs. The compounds were tested simultaneously under occluded patch tests covering DPCP-induced dermatitis. Inhibitory responses were assessed by visual scoring and measurements of the oedema thickness with ultrasound. RESULTS When applied both before and after the DPCP challenge, significant anti-inflammatory effects were seen in descending order for tacrolimus 0.1% ointment, clobetasol propionate ointment, betamethasone valerate ointment and hydrocortisone butyrate ointment, while pimecrolimus cream, hydrocortisone ointment and vehicles had no significant effect. Only tacrolimus ointment (P < 0.01) demonstrated a consistent significant pre-treatment inhibitory effect compared with an untreated DPCP control. CONCLUSIONS This human testing method in which the inflammation of experimentally induced allergic patch test reactions is quantified by objective measurement allows an analysis of the anti-inflammatory potency of not only topical corticosteroids, but also of drugs that have no effect on vasoconstriction. The method allowed comparison of the potencies of four topical corticosteroids and two calcineurin inhibitors.
Collapse
Affiliation(s)
- Kristian F Mose
- Department of Dermatology and Allergy Centre, Odense University Hospital, University of Southern Denmark, 5000, Odense C, Denmark.,Dermatological Investigations Scandinavia, J.B. Winsløwsvej 9, 5000, Odense C, Denmark
| | - Flemming Andersen
- Department of Dermatology and Allergy Centre, Odense University Hospital, University of Southern Denmark, 5000, Odense C, Denmark.,Dermatological Investigations Scandinavia, J.B. Winsløwsvej 9, 5000, Odense C, Denmark
| | - Mads A Røpke
- Department of Clinical Pharmacology, LEO Pharma A/S, 2750, Ballerup, Denmark
| | - Lone Skov
- Department of Dermato-Allergology, Herlev and Gentofte Hospital, University of Copenhagen, 2900, Hellerup, Denmark
| | - Peter S Friedmann
- Division of Infection, Inflammation & Immunity, Sir Henry Wellcome Laboratories, Southampton University Hospitals NHS Trust, Southampton, SO16 6YD, UK
| | - Klaus E Andersen
- Department of Dermatology and Allergy Centre, Odense University Hospital, University of Southern Denmark, 5000, Odense C, Denmark.,Dermatological Investigations Scandinavia, J.B. Winsløwsvej 9, 5000, Odense C, Denmark.,Centre for Innovative Medical Technology, Institute of Clinical Research, University of Southern Denmark, 5000, Odense C, Denmark
| |
Collapse
|
7
|
Røpke MA, Alonso C, Jung S, Norsgaard H, Richter C, Darvin ME, Litman T, Vogt A, Lademann J, Blume-Peytavi U, Kottner J. Effects of glucocorticoids on stratum corneum lipids and function in human skin—A detailed lipidomic analysis. J Dermatol Sci 2017; 88:330-338. [DOI: 10.1016/j.jdermsci.2017.08.009] [Citation(s) in RCA: 18] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/03/2017] [Revised: 06/29/2017] [Accepted: 08/17/2017] [Indexed: 12/11/2022]
|
8
|
Mose KF, Burton M, Thomassen M, Andersen F, Kruse TA, Tan Q, Skov L, Røpke MA, Litman T, Clemmensen O, Kristensen BW, Friedmann PS, Andersen KE. The gene expression and immunohistochemical time-course of diphenylcyclopropenone-induced contact allergy in healthy humans following repeated epicutaneous challenges. Exp Dermatol 2017; 26:926-933. [DOI: 10.1111/exd.13345] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 03/27/2017] [Indexed: 11/27/2022]
Affiliation(s)
- Kristian F. Mose
- Department of Dermatology and Allergy Centre; Odense University Hospital; University of Southern Denmark; Odense C Denmark
- Dermatological Investigations Scandinavia; Odense University Hospital; University of Southern Denmark; Odense C Denmark
| | - Mark Burton
- Department of Clinical Genetics; Odense University Hospital; University of Southern Denmark; Odense C Denmark
| | - Mads Thomassen
- Department of Clinical Genetics; Odense University Hospital; University of Southern Denmark; Odense C Denmark
| | - Flemming Andersen
- Department of Dermatology and Allergy Centre; Odense University Hospital; University of Southern Denmark; Odense C Denmark
- Dermatological Investigations Scandinavia; Odense University Hospital; University of Southern Denmark; Odense C Denmark
| | - Torben A. Kruse
- Department of Clinical Genetics; Odense University Hospital; University of Southern Denmark; Odense C Denmark
| | - Qihua Tan
- Department of Clinical Genetics; Odense University Hospital; University of Southern Denmark; Odense C Denmark
- Epidemiology, Biostatistics and Biodemography; Department of Public Health; University of Southern Denmark; Odense C Denmark
| | - Lone Skov
- Department of Dermato-Allergology; Herlev and Gentofte Hospital; University of Copenhagen; Hellerup Denmark
| | - Mads A. Røpke
- Departments of Clinical Pharmacology and Molecular Biomedicine; LEO Pharma A/S; Ballerup Denmark
| | - Thomas Litman
- Departments of Clinical Pharmacology and Molecular Biomedicine; LEO Pharma A/S; Ballerup Denmark
- Department of Immunology and Microbiology; University of Copenhagen; Copenhagen N Denmark
| | - Ole Clemmensen
- Department of Clinical Pathology; Odense University Hospital; University of Southern Denmark; Odense C Denmark
| | - Bjarne W. Kristensen
- Department of Clinical Pathology; Odense University Hospital; University of Southern Denmark; Odense C Denmark
| | - Peter S. Friedmann
- Division of Infection, Inflammation & Immunity; Sir Henry Wellcome Laboratories; Southampton University Hospitals NHS Trust; Southampton UK
| | - Klaus E. Andersen
- Department of Dermatology and Allergy Centre; Odense University Hospital; University of Southern Denmark; Odense C Denmark
- Dermatological Investigations Scandinavia; Odense University Hospital; University of Southern Denmark; Odense C Denmark
- Centre for Innovative Medical Technology; Institute of Clinical Research; University of Southern Denmark; Odense C Denmark
| |
Collapse
|
9
|
Mose KF, Andersen F, Skov L, Røpke MA, Litman T, Friedmann PS, Andersen KE. Repeated monthly epicutaneous challenges with diphenylcyclopropenone result in a clinically reproducible level of contact allergy in de novo sensitized individuals. Br J Dermatol 2017; 176:1095-1097. [PMID: 27515376 DOI: 10.1111/bjd.14949] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Affiliation(s)
- K F Mose
- Department of Dermatology and Allergy Centre, Odense University Hospital, University of Southern Denmark, 5000, Odense C, Denmark.,Dermatological Investigations Scandinavia, Odense University Hospital, University of Southern Denmark, 5000, Odense C, Denmark
| | - F Andersen
- Department of Dermatology and Allergy Centre, Odense University Hospital, University of Southern Denmark, 5000, Odense C, Denmark.,Dermatological Investigations Scandinavia, Odense University Hospital, University of Southern Denmark, 5000, Odense C, Denmark
| | - L Skov
- Department of Dermato-Allergology, Herlev and Gentofte Hospital, University of Copenhagen, 2900, Hellerup, Denmark
| | - M A Røpke
- LEO Pharma A/S, Departments of Clinical Pharmacology and Molecular Biomedicine, 2750, Ballerup, Denmark
| | - T Litman
- LEO Pharma A/S, Departments of Clinical Pharmacology and Molecular Biomedicine, 2750, Ballerup, Denmark.,Department of Immunology and Microbiology, University of Copenhagen, 2200, Copenhagen N, Denmark
| | - P S Friedmann
- Division of Infection, Inflammation and Immunity, University of Southampton School of Medicine, Southampton, U.K
| | - K E Andersen
- Department of Dermatology and Allergy Centre, Odense University Hospital, University of Southern Denmark, 5000, Odense C, Denmark.,Dermatological Investigations Scandinavia, Odense University Hospital, University of Southern Denmark, 5000, Odense C, Denmark.,Centre for Innovative Medical Technology, Institute of Clinical Research, Odense University Hospital, University of Southern Denmark, 5000, Odense C, Denmark
| |
Collapse
|
10
|
Lovato P, Norsgaard H, Tokura Y, Røpke MA. Corrigendum to “Calcipotriol and betamethasone dipropionate exert additive inhibitory effects on the cytokine expression of inflammatory dendritic cell-Th17 cell axis in psoriasis” [J. Dermatol. Sci. 81 (2016) 153–164]. J Dermatol Sci 2017; 85:147. [DOI: 10.1016/j.jdermsci.2016.12.001] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
11
|
Løvendorf MB, Dyring-Andersen B, Vennegaard MT, Clemmensen A, Bonefeld CM, Røpke MA, Skov L. Allergic contact dermatitis to nickel is characterized by a specific micro-RNA signature. Dermatitis 2016; 26:195-6. [PMID: 26172492 DOI: 10.1097/der.0000000000000127] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
Affiliation(s)
- Marianne B Løvendorf
- Department of Dermato-Allergology, Gentofte Hospital, University of Copenhagen, Hellerup, Denmark Department of Dermato-Allergology, Gentofte Hospital, University of Copenhagen, Hellerup, Denmark Department of International Health, Immunology, and Microbiology, University of Copenhagen, Copenhagen, Denmark Department of Dermatology, Bispebjerg Hospital, University of Copenhagen, Copenhagen, Denmark Department of International Health, Immunology, and Microbiology, University of Copenhagen, Copenhagen, Denmark LEO Pharma A/S, Ballerup, Denmark Department of Dermato-Allergology, Gentofte Hospital, University of Copenhagen, Hellerup, Denmark
| | | | | | | | | | | | | |
Collapse
|
12
|
Lovato P, Norsgaard H, Tokura Y, Røpke MA. Calcipotriol and betamethasone dipropionate exert additive inhibitory effects on the cytokine expression of inflammatory dendritic cell–Th17 cell axis in psoriasis. J Dermatol Sci 2016; 81:153-64. [DOI: 10.1016/j.jdermsci.2015.12.009] [Citation(s) in RCA: 48] [Impact Index Per Article: 6.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/28/2015] [Revised: 12/02/2015] [Accepted: 12/21/2015] [Indexed: 01/20/2023]
|
13
|
Løvendorf MB, Mitsui H, Zibert JR, Røpke MA, Hafner M, Dyring-Andersen B, Bonefeld CM, Krueger JG, Skov L. Laser capture microdissection followed by next-generation sequencing identifies disease-related microRNAs in psoriatic skin that reflect systemic microRNA changes in psoriasis. Exp Dermatol 2015; 24:187-93. [PMID: 25431026 DOI: 10.1111/exd.12604] [Citation(s) in RCA: 48] [Impact Index Per Article: 5.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 11/23/2014] [Indexed: 12/16/2022]
Abstract
Psoriasis is a systemic disease with cutaneous manifestations. MicroRNAs (miRNAs) are small non-coding RNA molecules that are differentially expressed in psoriatic skin; however, only few cell- and region-specific miRNAs have been identified in psoriatic lesions. We used laser capture microdissection (LCM) and next-generation sequencing (NGS) to study the specific miRNA expression profiles in the epidermis (Epi) and dermal inflammatory infiltrates (RD) of psoriatic skin (N = 6). We identified 24 deregulated miRNAs in the Epi and 37 deregulated miRNAs in the RD of psoriatic plaque compared with normal psoriatic skin (FCH > 2, FDR < 0.05). Interestingly, 9 of the 37 miRNAs in RD, including miR-193b and miR-223, were recently described as deregulated in circulating peripheral blood mononuclear cells (PBMCs) from patients with psoriasis. Using flow cytometry and qRT-PCR, we found that miR-193b and miR-223 were expressed in Th17 cells. In conclusion, we demonstrate that LCM combined with NGS provides a robust approach to explore the global miRNA expression in the epidermal and dermal compartments of psoriatic skin. Furthermore, our results indicate that the altered local miRNA changes seen in the RD are reflected in the circulating immune cells, suggesting that miRNAs may contribute to the pathogenesis of psoriasis.
Collapse
Affiliation(s)
- Marianne B Løvendorf
- Department of Dermato-Allergology, Gentofte Hospital, University of Copenhagen, Hellerup, Denmark; LEO Pharma A/S, Ballerup, Denmark
| | | | | | | | | | | | | | | | | |
Collapse
|
14
|
Løvendorf MB, Zibert JR, Gyldenløve M, Røpke MA, Skov L. MicroRNA-223 and miR-143 are important systemic biomarkers for disease activity in psoriasis. J Dermatol Sci 2014; 75:133-9. [PMID: 24909097 DOI: 10.1016/j.jdermsci.2014.05.005] [Citation(s) in RCA: 68] [Impact Index Per Article: 6.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/15/2014] [Revised: 05/07/2014] [Accepted: 05/13/2014] [Indexed: 12/18/2022]
Abstract
BACKGROUND Psoriasis is a systemic inflammatory skin disease. MicroRNAs (miRNAs) are a class of small non-coding RNA molecules that recently have been found in the blood to be relevant as disease biomarkers. OBJECTIVE We aimed to explore miRNAs potential as blood biomarkers for psoriasis. METHODS Using microarray and quantitative real-time PCR we measured the global miRNA expression in whole blood, plasma and peripheral blood mononuclear cells (PBMCs) from patients with psoriasis and healthy controls. RESULTS We identified several deregulated miRNAs in the blood from patients with psoriasis including miR-223 and miR-143 which were found to be significantly upregulated in the PBMCs from patients with psoriasis compared with healthy controls (FCH=1.63, P<0.01; FCH=2.18, P<0.01, respectively). In addition, miR-223 and miR-143 significantly correlated with the PASIscore (r=0.46, P<0.05; r=0.55, P<0.02, respectively). Receiver-operating characteristic analysis (ROC) showed that miR-223 and -143 have the potential to distinguish between psoriasis and healthy controls (miR-223: area under the curve (AUC)=0.80, miR-143: AUC=0.75). Interestingly, after 3-5 weeks of treatment with methotrexate following a significant decrease in psoriasis severity, miR-223 and miR-143 were significantly downregulated in the PBMCs from patients with psoriasis. CONCLUSION We suggest that changes in the miR-223 and miR-143 expressions in PBMCs from patients with psoriasis may serve as novel biomarkers for disease activity in psoriasis; however, further investigations are warranted to clarify their specific roles.
Collapse
Affiliation(s)
- Marianne B Løvendorf
- Department of Dermato-Allergology, Gentofte Hospital, University of Copenhagen, Niels Andersens Vej 65, 2900 Hellerup, Denmark; LEO Pharma A/S, Industriparken 55, 2750 Ballerup, Denmark.
| | - John R Zibert
- LEO Pharma A/S, Industriparken 55, 2750 Ballerup, Denmark
| | - Mette Gyldenløve
- Department of Dermato-Allergology, Gentofte Hospital, University of Copenhagen, Niels Andersens Vej 65, 2900 Hellerup, Denmark
| | - Mads A Røpke
- LEO Pharma A/S, Industriparken 55, 2750 Ballerup, Denmark
| | - Lone Skov
- Department of Dermato-Allergology, Gentofte Hospital, University of Copenhagen, Niels Andersens Vej 65, 2900 Hellerup, Denmark
| |
Collapse
|
15
|
Marstrand T, Ahler CB, Ralfkiaer U, Clemmensen A, Kopp KL, Sibbesen NA, Krejsgaard T, Litman T, Wasik MA, Bonefeld CM, Grønbæk K, Gjerdum LMR, Gniadecki R, Ralfkiaer E, Geisler C, Woetmann A, Røpke MA, Glue C, Skov L, Odum N. Validation of a diagnostic microRNA classifier in cutaneous T-cell lymphomas. Leuk Lymphoma 2013; 55:957-8. [DOI: 10.3109/10428194.2013.815352] [Citation(s) in RCA: 25] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
|
16
|
Løvendorf MB, Zibert JR, Hagedorn PH, Glue C, Ødum N, Røpke MA, Skov L. Comparison of microRNA expression using different preservation methods of matched psoriatic skin samples. Exp Dermatol 2012; 21:299-301. [PMID: 22417307 DOI: 10.1111/j.1600-0625.2012.01445.x] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/15/2023]
Abstract
MicroRNAs are non-coding RNA molecules modulating gene expression post-transcriptionally. Formalin-fixed, paraffin-embedding (FFPE) is a standard preservation method often used in clinical practices, but induces RNA degradation. Extracting high-quality RNA from human skin can be challenging as skin contains high levels of RNases. As microRNAs are 19-23 nucleotides long and lack a poly-A tail, they may be less prone to RNA degradation than mRNAs. We investigated whether microRNAs in psoriatic (FFPE) samples reliably reflect microRNA expression in samples less prone to RNA degradation such as fresh-frozen (FS) and Tissue-Tek-embedding (OCT). We found a strong correlation of the microRNA expression levels between all preservation methods of matched psoriatic skin samples (r(s) ranging from 0.91 to 0.95 (P < 0.001)). These observations were further confirmed with qRT-PCR. Our results demonstrate that microRNA detection in human skin is robust irrespective of preservation method; thus, microRNAs offer an appropriate and flexible approach in clinical practices and for diagnostic purposes in skin disorders.
Collapse
|
17
|
|
18
|
Kvist PH, Svensson L, Hagberg O, Hoffmann V, Kemp K, Røpke MA. Comparison of the effects of vitamin D products in a psoriasis plaque test and a murine psoriasis xenograft model. J Transl Med 2009; 7:107. [PMID: 20017943 PMCID: PMC2804591 DOI: 10.1186/1479-5876-7-107] [Citation(s) in RCA: 13] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/08/2009] [Accepted: 12/17/2009] [Indexed: 11/23/2022] Open
Abstract
The aim of the present study was to compare the effects of Daivobet® and calcipotriol on clinical score and biomarker responses in a modified version of the Scholtz-Dumas psoriasis plaque assay. Furthermore, it was the aim to compare the effects of calcipotriol and betamethasone in the murine psoriasis xenograft model. Twenty four patients with psoriasis were treated topically once daily for three weeks, whereas the grafted mice were treated for four weeks. Clinical responses were scored twice weekly and biopsies were taken at the end of each study to analyse for skin biomarkers by histology and immunohistochemistry. The results clearly demonstrate effects on both clinical signs and biomarkers. In the patient study the total clinical score was reduced significantly with both Daivobet® and calcipotriol. Both treatments reduced epidermal thickness, Ki-67 and cytokeratin 16 expression. T cell infiltration was significantly reduced by Daivobet® but only marginally by calcipotriol. Both treatments showed strong effects on the epidermal psoriatic phenotype. Results from the xenograft model essentially showed the same results. However differences were observed when investigating subtypes of T cells. The study demonstrates the feasibility of obtaining robust biomarker data in the psoriasis plaque test that correlate well with those obtained in other clinical studies. Furthermore, the biomarker data from the plaque test correlate with biopsy data from the grafted mice.
Collapse
Affiliation(s)
- Peter H Kvist
- Department of Disease Pharmacology, LEO Pharma A/S, Industriparken 55, DK-2750 Ballerup, Denmark.
| | | | | | | | | | | |
Collapse
|